Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: Relationship with glutamate release in the medial prefrontal cortex

Mirjana Carli, Eleonora Calcagno, Pierangela Mainolfi, Ester Mainini, Roberto W. Invernizzi

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Rationale: Disruption in cognition is characteristic of psychiatric illnesses such as schizophrenia. Studies of drugs that improve cognition might provide a better insight into the mechanisms underlying cognitive deficits. Objectives: We compared the effects of the antipsychotic drugs aripiprazole, olanzapine, and haloperidol on performance deficit in a test of divided and sustained visual attention, the five-choice serial reaction time task (5-CSRTT), which provides information on attentional functioning (accuracy of visual discrimination), response control (measured by anticipatory and perseverative responses) and speed. Methods: The cognitive deficit was induced by infusion of the competitive NMDA receptor antagonist 3-(R)-2-carboxypiperazin-4-propyl-1- phosphonic acid (CPP) in the rat medial prefrontal cortex (mPFC). In vivo microdialysis was used to compare the effects of aripiprazole, olanzapine and haloperidol on CPP-induced glutamate (GLU) and serotonin (5-HT) release in the mPFC of conscious rats. Results: Oral aripiprazole (1.0 and 3.0 mg/kg) and olanzapine (0.3 and 1.0 mg/kg), but not haloperidol (0.1 mg/kg), abolished the CPP-induced accuracy deficit and GLU release. Haloperidol and aripiprazole, but not olanzapine, reduced perseverative over-responding, while anticipatory responding was best controlled by olanzapine. However, these effects were not associated with changes in GLU release. No association was found between the effects of these antipsychotics on CPP-induced attentional performance deficits in the 5-CSRTT and 5-HT efflux. Conclusions: The data confirm that excessive GLU release in the mPFC is associated with attentional deficits. Thus, suppression of GLU release may be a target for the development of novel antipsychotic drugs with greater effect on some aspects of cognitive deficits.

Original languageEnglish
Pages (from-to)639-652
Number of pages14
JournalPsychopharmacology
Volume214
Issue number3
DOIs
Publication statusPublished - Apr 2011

Fingerprint

olanzapine
Haloperidol
Prefrontal Cortex
Glutamic Acid
Schizophrenia
Antipsychotic Agents
Serotonin
Cognition
Microdialysis
N-Methyl-D-Aspartate Receptors
Reaction Time
Psychiatry
Aripiprazole
3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid

Keywords

  • Antipsychotics
  • Cognitive deficits
  • Glutamate release
  • Medial prefrontal cortex
  • NMDA receptor antagonists

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats : Relationship with glutamate release in the medial prefrontal cortex. / Carli, Mirjana; Calcagno, Eleonora; Mainolfi, Pierangela; Mainini, Ester; Invernizzi, Roberto W.

In: Psychopharmacology, Vol. 214, No. 3, 04.2011, p. 639-652.

Research output: Contribution to journalArticle

@article{046e3d0fb3a944a595d2f1ef0e83e156,
title = "Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: Relationship with glutamate release in the medial prefrontal cortex",
abstract = "Rationale: Disruption in cognition is characteristic of psychiatric illnesses such as schizophrenia. Studies of drugs that improve cognition might provide a better insight into the mechanisms underlying cognitive deficits. Objectives: We compared the effects of the antipsychotic drugs aripiprazole, olanzapine, and haloperidol on performance deficit in a test of divided and sustained visual attention, the five-choice serial reaction time task (5-CSRTT), which provides information on attentional functioning (accuracy of visual discrimination), response control (measured by anticipatory and perseverative responses) and speed. Methods: The cognitive deficit was induced by infusion of the competitive NMDA receptor antagonist 3-(R)-2-carboxypiperazin-4-propyl-1- phosphonic acid (CPP) in the rat medial prefrontal cortex (mPFC). In vivo microdialysis was used to compare the effects of aripiprazole, olanzapine and haloperidol on CPP-induced glutamate (GLU) and serotonin (5-HT) release in the mPFC of conscious rats. Results: Oral aripiprazole (1.0 and 3.0 mg/kg) and olanzapine (0.3 and 1.0 mg/kg), but not haloperidol (0.1 mg/kg), abolished the CPP-induced accuracy deficit and GLU release. Haloperidol and aripiprazole, but not olanzapine, reduced perseverative over-responding, while anticipatory responding was best controlled by olanzapine. However, these effects were not associated with changes in GLU release. No association was found between the effects of these antipsychotics on CPP-induced attentional performance deficits in the 5-CSRTT and 5-HT efflux. Conclusions: The data confirm that excessive GLU release in the mPFC is associated with attentional deficits. Thus, suppression of GLU release may be a target for the development of novel antipsychotic drugs with greater effect on some aspects of cognitive deficits.",
keywords = "Antipsychotics, Cognitive deficits, Glutamate release, Medial prefrontal cortex, NMDA receptor antagonists",
author = "Mirjana Carli and Eleonora Calcagno and Pierangela Mainolfi and Ester Mainini and Invernizzi, {Roberto W.}",
year = "2011",
month = "4",
doi = "10.1007/s00213-010-2065-7",
language = "English",
volume = "214",
pages = "639--652",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats

T2 - Relationship with glutamate release in the medial prefrontal cortex

AU - Carli, Mirjana

AU - Calcagno, Eleonora

AU - Mainolfi, Pierangela

AU - Mainini, Ester

AU - Invernizzi, Roberto W.

PY - 2011/4

Y1 - 2011/4

N2 - Rationale: Disruption in cognition is characteristic of psychiatric illnesses such as schizophrenia. Studies of drugs that improve cognition might provide a better insight into the mechanisms underlying cognitive deficits. Objectives: We compared the effects of the antipsychotic drugs aripiprazole, olanzapine, and haloperidol on performance deficit in a test of divided and sustained visual attention, the five-choice serial reaction time task (5-CSRTT), which provides information on attentional functioning (accuracy of visual discrimination), response control (measured by anticipatory and perseverative responses) and speed. Methods: The cognitive deficit was induced by infusion of the competitive NMDA receptor antagonist 3-(R)-2-carboxypiperazin-4-propyl-1- phosphonic acid (CPP) in the rat medial prefrontal cortex (mPFC). In vivo microdialysis was used to compare the effects of aripiprazole, olanzapine and haloperidol on CPP-induced glutamate (GLU) and serotonin (5-HT) release in the mPFC of conscious rats. Results: Oral aripiprazole (1.0 and 3.0 mg/kg) and olanzapine (0.3 and 1.0 mg/kg), but not haloperidol (0.1 mg/kg), abolished the CPP-induced accuracy deficit and GLU release. Haloperidol and aripiprazole, but not olanzapine, reduced perseverative over-responding, while anticipatory responding was best controlled by olanzapine. However, these effects were not associated with changes in GLU release. No association was found between the effects of these antipsychotics on CPP-induced attentional performance deficits in the 5-CSRTT and 5-HT efflux. Conclusions: The data confirm that excessive GLU release in the mPFC is associated with attentional deficits. Thus, suppression of GLU release may be a target for the development of novel antipsychotic drugs with greater effect on some aspects of cognitive deficits.

AB - Rationale: Disruption in cognition is characteristic of psychiatric illnesses such as schizophrenia. Studies of drugs that improve cognition might provide a better insight into the mechanisms underlying cognitive deficits. Objectives: We compared the effects of the antipsychotic drugs aripiprazole, olanzapine, and haloperidol on performance deficit in a test of divided and sustained visual attention, the five-choice serial reaction time task (5-CSRTT), which provides information on attentional functioning (accuracy of visual discrimination), response control (measured by anticipatory and perseverative responses) and speed. Methods: The cognitive deficit was induced by infusion of the competitive NMDA receptor antagonist 3-(R)-2-carboxypiperazin-4-propyl-1- phosphonic acid (CPP) in the rat medial prefrontal cortex (mPFC). In vivo microdialysis was used to compare the effects of aripiprazole, olanzapine and haloperidol on CPP-induced glutamate (GLU) and serotonin (5-HT) release in the mPFC of conscious rats. Results: Oral aripiprazole (1.0 and 3.0 mg/kg) and olanzapine (0.3 and 1.0 mg/kg), but not haloperidol (0.1 mg/kg), abolished the CPP-induced accuracy deficit and GLU release. Haloperidol and aripiprazole, but not olanzapine, reduced perseverative over-responding, while anticipatory responding was best controlled by olanzapine. However, these effects were not associated with changes in GLU release. No association was found between the effects of these antipsychotics on CPP-induced attentional performance deficits in the 5-CSRTT and 5-HT efflux. Conclusions: The data confirm that excessive GLU release in the mPFC is associated with attentional deficits. Thus, suppression of GLU release may be a target for the development of novel antipsychotic drugs with greater effect on some aspects of cognitive deficits.

KW - Antipsychotics

KW - Cognitive deficits

KW - Glutamate release

KW - Medial prefrontal cortex

KW - NMDA receptor antagonists

UR - http://www.scopus.com/inward/record.url?scp=79953671632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953671632&partnerID=8YFLogxK

U2 - 10.1007/s00213-010-2065-7

DO - 10.1007/s00213-010-2065-7

M3 - Article

C2 - 21052982

AN - SCOPUS:79953671632

VL - 214

SP - 639

EP - 652

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 3

ER -